论文部分内容阅读
经皮冠状动脉介入治疗已经成为冠状动脉粥样硬化性心脏病的重要治疗手段,炎性反应贯穿于支架植入术中及术后,并成为支架术后再狭窄的关键性因素。治疗的目的一方面要防止细胞增殖和血管壁的重构,一方面要减少局部和机体系统的持续炎性反应,抗血小板药物、他汀类药物、药物涂层支架等从各环节抑制支架术后炎性反应,降低再狭窄的发生率。内皮祖细胞在防止再狭窄中有望得到良好应用,生物可降解支架可能为患者带来更大的益处。
Percutaneous coronary intervention has become an important treatment of coronary atherosclerotic heart disease. Inflammatory reaction runs through and after stent implantation and becomes the key factor of restenosis after stent implantation. On the one hand, the purpose of treatment is to prevent cell proliferation and remodeling of the vascular wall, on the one hand, to reduce the persistent inflammatory reaction in the local and systemic systems; to inhibit the proliferation of anti-platelet drugs, statins and drug- Inflammatory reaction, reducing the incidence of restenosis. Endothelial progenitor cells in the prevention of restenosis is expected to be well-used, biodegradable scaffolds may bring greater benefits to patients.